Literature DB >> 21403980

Recent insights into the pathogenesis of type AA amyloidosis.

J C H van der Hilst1.   

Abstract

The amyloidoses are a group of life-threatening diseases in which fibrils made of misfolded proteins are deposited in organs and tissues. The fibrils are stable, insoluble aggregates of precursor proteins that have adopted an antiparallel beta-sheet structure. In type AA, or reactive, amyloidosis, the precursor protein of the fibrils is serum amyloid A (SAA). SAA is a 104-amino-acid protein that is produced in the liver in response to proinflammatory cytokines. Although the protein that is produced by the liver contains 104 amino acids, only the N-terminal 66-76 amino acids are found in amyloid fibrils. Furthermore, SAA has been shown to have an alpha-helical structure primarily. Thus, for SAA to be incorporated into an amyloid fibril, two processes have to occur: C-terminal cleavage and conversion into a beta-sheet. Only a minority of patients with elevated SAA levels develop amyloidosis. Factors that contribute to the risk of amyloidosis include the duration and degree of SAA elevation, polymorphisms in SAA, and the type of autoinflammatory syndrome. In the Hyper-IgD syndrome, amyloidosis is less prevalent than in the other autoinflammatory diseases. In vitro work has shown that the isoprenoid pathway influences amyloidogenesis by farnesylated proteins. Although many proteins contain domains that have a potential for self-aggregation, amyloidosis is only a very rare event. Heat shock proteins (HSPs) are chaperones that assist other proteins to attain, maintain, and regain a functional conformation. In this review, recent insights into the pathogenesis of amyloidosis are discussed, in addition to a new hypothesis for a role of HSPs in the pathogenesis of type AA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21403980      PMCID: PMC5720109          DOI: 10.1100/tsw.2011.64

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  19 in total

1.  Importance of serum amyloid-A in Behçet's disease.

Authors:  Mehmet Agilli; Fevzi Nuri Aydin; Yasemin Gulcan Kurt; Tuncer Cayci
Journal:  Clin Rheumatol       Date:  2015-01-14       Impact factor: 2.980

2.  Influence of the carboxy terminus of serum amyloid A on protein oligomerization, misfolding, and fibril formation.

Authors:  Sanket Patke; Ronak Maheshwari; Jeffrey Litt; Saipraveen Srinivasan; J Javier Aguilera; Wilfredo Colón; Ravi S Kane
Journal:  Biochemistry       Date:  2012-03-26       Impact factor: 3.162

3.  Mean platelet volume as a potential predictor of proteinuria and amyloidosis in familial Mediterranean fever.

Authors:  Hale Sakallı; Oznur Kal
Journal:  Clin Rheumatol       Date:  2013-04-17       Impact factor: 2.980

4.  Reactive amyloidosis associated with ischial callosititis: a report with histology of ischial callosities in rhesus macaques (Macaca mulatta).

Authors:  David X Liu; Margaret H Gilbert; Xiaolei Wang; Peter J Didier; Ronald S Veazey
Journal:  J Vet Diagn Invest       Date:  2012-11       Impact factor: 1.279

Review 5.  Amyloidosis in Heart Failure.

Authors:  Sandra Ihne; Caroline Morbach; Laura Obici; Giovanni Palladini; Stefan Störk
Journal:  Curr Heart Fail Rep       Date:  2019-12

6.  Cleavage, Downregulation, and Aggregation of Serum Amyloid A.

Authors:  Wenhua Wang; Prabir Khatua; Ulrich H E Hansmann
Journal:  J Phys Chem B       Date:  2020-01-30       Impact factor: 2.991

7.  Serum apolipoprotein C-II is prognostic for survival after pancreatic resection for adenocarcinoma.

Authors:  A Xue; J W Chang; L Chung; J Samra; T Hugh; A Gill; G Butturini; R C Baxter; R C Smith
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

8.  Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation.

Authors:  Isabel Romero-Camarero; Xiaoyu Jiang; Yasodha Natkunam; Xiaoqing Lu; Carolina Vicente-Dueñas; Ines Gonzalez-Herrero; Teresa Flores; Juan Luis Garcia; George McNamara; Christian Kunder; Shuchun Zhao; Victor Segura; Lorena Fontan; Jose A Martínez-Climent; Francisco Javier García-Criado; Jason D Theis; Ahmet Dogan; Elena Campos-Sánchez; Michael R Green; Ash A Alizadeh; Cesar Cobaleda; Isidro Sánchez-García; Izidore S Lossos
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  Review of eprodisate for the treatment of renal disease in AA amyloidosis.

Authors:  Adam Rumjon; Thomas Coats; Muhammad M Javaid
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-02-24

10.  Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis.

Authors:  Jonathan S Wall; Emily B Martin; Tina Richey; Alan C Stuckey; Sallie Macy; Craig Wooliver; Angela Williams; James S Foster; Penney McWilliams-Koeppen; Ed Uberbacher; Xiaolin Cheng; Stephen J Kennel
Journal:  Molecules       Date:  2015-04-27       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.